Chimerix’s (CMRX) “Buy” Rating Reaffirmed at HC Wainwright

Chimerix (NASDAQ:CMRX)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $11.00 target price on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 227.38% from the stock’s previous close.

Separately, Wedbush restated an “outperform” rating and set a $6.00 target price on shares of Chimerix in a report on Tuesday, December 10th.

Chimerix Stock Performance

Shares of Chimerix stock traded down $0.10 during trading on Monday, hitting $3.36. 752,611 shares of the stock were exchanged, compared to its average volume of 1,267,767. Chimerix has a 12 month low of $0.75 and a 12 month high of $3.67. The stock has a market cap of $302.18 million, a PE ratio of -3.57 and a beta of 1.02. The stock’s fifty day moving average is $1.50 and its 200 day moving average is $1.11.

Institutional Trading of Chimerix

A number of large investors have recently bought and sold shares of the stock. Marshall Wace LLP bought a new position in shares of Chimerix in the second quarter worth about $137,000. Connor Clark & Lunn Investment Management Ltd. raised its position in Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 138,098 shares during the last quarter. Finally, Valeo Financial Advisors LLC lifted its holdings in Chimerix by 566.9% during the 3rd quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 69,505 shares in the last quarter. 45.42% of the stock is currently owned by institutional investors.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.